Aligos Therapeutics Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative therapies to treat viral infections and liver diseases. The company is based in South San Francisco, California, and was founded in 2018. Aligos' mission is to improve patient outcomes by developing new treatments that address unmet medical needs in these important therapeutic areas.
Aligos' product portfolio includes several novel therapies for viral infections and liver diseases that are currently in clinical development. These include a range of small molecule inhibitors and nucleic acid-based therapies that are designed to target the underlying mechanisms of these diseases and provide improved outcomes for patients. Aligos' therapies have the potential to address a broad range of viral infections, including hepatitis B and C, as well as other liver diseases such as nonalcoholic steatohepatitis (NASH).
Aligos is committed to innovation and collaboration, and is working closely with leading academic and industry partners to advance the field of viral infection and liver disease therapeutics. The company has a strong management team with deep experience in drug discovery and development, and is well-funded with significant financial support from leading life sciences investors. With a strong portfolio of innovative therapies, a focus on collaboration and innovation, and a commitment to improving patient outcomes in viral infections and liver diseases, Aligos is well-positioned to continue making significant strides in these important therapeutic areas.